Kubota K, Kuroda J, Yoshida M, Okada A, Deguchi T, Kitajima M
K. Kubota, M.D., Ph.D., Department of Gastroenterological Surgery, International University of Health and Welfare Mita Hospital, Mita 1-4-3, Minato-ku, Tokyo 108-8329, Japan, Tel: +81-3-3451-8121; Fax: +81-3-3454-0067; E-mail:
J Nutr Health Aging. 2014 Apr;18(4):437-40. doi: 10.1007/s12603-014-0018-2.
Surgeries for cancer of the esophagus are still associated with a high rate of postoperative morbidity. There are few reports of perioperative nutritional support for patients undergoing esophageal cancer surgery, and there is insufficient evidence to recommend routine use of immunonutrition in these patients. The aim of this study was to determine whether preoperative immunonutrition positively influences key clinical outcomes such as postoperative infectious complications, mortality, length of hospital stay, and short-term survival in this population.
We undertook a retrospective investigation of the effects of preoperative nutritional support on the postoperative course of esophageal cancer surgery at the Department of Gastroenterological Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Fifty-five patients who underwent esophagectomy for esophageal cancer were included in this study. Of the 55 patients, 26 patients consumed a liquid dietary supplement (IMPACT group) before surgery and 29 patients did not (STANDARD group).
Before surgery, the IMPACT group consumed 750 ml (3 packs)/day of Impact for 5 consecutive days.
The analysis was based on postoperative complications, hospital mortality, length of hospital stay, and short-term survival.
Significantly fewer patients developed postoperative infections in the IMPACT group compared with the STANDARD group (p=.007): 4 of 21 patients in the IMPACT group and 10 of 29 patients in the STANDARD group. Either an infectious complication or another complication developed in 8 patients in the IMPACT group and 13 patients in the STANDARD group, with the result that 6 patients in the STANDARD group died of postoperative complications (p=.001). The duration of hospitalization was 34 days in the IMPACT group and 48 days in the STANDARD group; hence, hospitalization was significantly shorter in patients treated with Impact (p=.008). The mean 6-month survival rates for the IMPACT group and the STANDARD group were 92% (24/26) and 72% (21/29), respectively (p=.028).
Simple preoperative supplementation significantly improved outcome. Administration of the supplemental diet before esophageal surgery appeared to be an effective strategy in reducing infectious complications, mortality, and hospitalization, and improving short-term survival.
食管癌手术的术后发病率仍然很高。关于接受食管癌手术患者围手术期营养支持的报道很少,且没有足够证据推荐在这些患者中常规使用免疫营养。本研究的目的是确定术前免疫营养是否会对该人群的关键临床结局产生积极影响,如术后感染并发症、死亡率、住院时间和短期生存率。
我们对日本东京国际医疗福祉大学三田医院胃肠外科术前营养支持对食管癌手术术后过程的影响进行了回顾性调查。
本研究纳入了55例行食管癌切除术的患者。在这55例患者中,26例患者在手术前食用了液体膳食补充剂(IMPACT组),29例患者未食用(标准组)。
手术前,IMPACT组连续5天每天饮用750毫升(3包)Impact。
分析基于术后并发症、医院死亡率、住院时间和短期生存率。
与标准组相比,IMPACT组术后发生感染的患者明显更少(p = 0.007):IMPACT组21例患者中有4例发生感染,标准组29例患者中有10例发生感染。IMPACT组8例患者和标准组13例患者发生了感染并发症或其他并发症,结果标准组有6例患者死于术后并发症(p = 0.001)。IMPACT组的住院时间为34天,标准组为48天;因此,接受Impact治疗的患者住院时间明显更短(p = 0.008)。IMPACT组和标准组的平均6个月生存率分别为92%(24/26)和72%(21/29)(p = 0.028)。
简单的术前补充显著改善了结局。食管癌手术前给予补充饮食似乎是减少感染并发症、死亡率和住院时间以及提高短期生存率的有效策略。